Evidence map›Paper›PMID 21423761›Full record

ArticlePloS one2011

Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization.

Fiona Kate Elizabeth McDuff, Suzanne Dawn Turner

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. ALK-immunoreactive neoplasms.International journal of clinical and experimental pathology · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Fiona Kate Elizabeth McDuffDivision of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom.
Suzanne Dawn Turner
Cambridge School · PTUniversity of Cambridge · GB

Funding

Cancer Research UK C19666Wellcome Trust
6 · The paper itself

Abstract

Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase aberrantly expressed in a variety of tumor types, most notably in Anaplastic Large Cell Lymphoma (ALCL) where a chromosomal translocation generates the oncogenic fusion protein, Nucleophosmin-ALK (NPM-ALK). Whilst much is known regarding the mechanism of transformation by NPM-ALK, the existence of cellular defence pathways to prevent this pathological process has not been investigated. Employing the highly tractable primary murine embryonic fibroblast (MEF) system we show that cellular transformation is not an inevitable consequence of NPM-ALK activity but is combated by p53 and Rb. Activation of p53 and/or Rb by NPM-ALK triggers a potent proliferative block with features reminiscent of senescence. While loss of p53 alone is sufficient to circumvent NPM-ALK-induced senescence and permit cellular transformation, sole loss of Rb permits continued proliferation but not transformation due to p53-imposed restraints. Furthermore, NPM-ALK attenuates p53 activity in an Rb and MDM2 dependent manner but this activity is not sufficient to bypass senescence. These data indicate that senescence may constitute an effective barrier to ALK-induced malignancies that ultimately must be overcome for tumor development.

Indexed as

Cellular SenescenceAnaplastic Lymphoma KinaseAnimalsCell AdhesionCell CycleCell ProliferationCells, CulturedCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p16Embryo, MammalianFibroblastsHumansMiceModels, BiologicalMutationProtein Processing, Post-TranslationalALK protein, humanAlk protein, mouseAnaplastic Lymphoma KinaseCyclin-Dependent Kinase Inhibitor p16p80(NPM-ALK) proteinProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesRetinoblastoma ProteinTumor Suppressor Protein p53

Identifiers

PMID21423761
PMCPMC3056788
OpenAlexW2006025884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.